Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
Titel:
Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
Auteur:
Spicer, J. Baird, R. Suder, A. Cresti, N. Corbacho, J. Garcia Hogarth, L. Frenkel, E. Matsumoto, S. Kawabata, I. Donaldson, K. Posner, J. Sarker, D. Jodrell, D. Plummer, R.